subject,visit,Family,cnt,pct,sample_id,ship_id,bio_inventory_group_name,bio_inventory_registration_number,originating_id,collection_date,participant_id,saffl,mittfl,siteid,site,age,sexcat,racecat,ethcat,stage_dx,stage_enrl,melanoma_subtype,nras,braf,rumino_scrn,treatment_name.x,rand_date,trt_disc_reas,trt_last_day,study_disc_reas,study_last_day,death_cause,death_day,best_overall_response.x,s_ddur,dcr.x,orr,pct_chg_target_lesions,sgpid,batch,mb_pass_protocol_qc_wms,mb_note_protocol_qc_wms,mb_pass_samp_hand_qc_wms,mb_note_samp_hand_qc_wms,dcr.y,cd8percent_bl,cd8percent_ot,arm,pfs_months,pfs_censored,os_months,os_censored,timepoint,treatment_name.y,best_overall_response.y,confirmation,sd_duration,bor
102-S0001,BL,f__Ruminococcaceae,10337464,9.89966592593126,SGP033297,Ship_6425,Stool - OmniGut Aliquot,A124BT720-001,BK01547ST02-01,2/19/19,PICI0014-102-S0001,Y,Y,102,MD Anderson Cancer Center,72,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Active,2/26/19,PROGRESSIVE DISEASE,188,COMPLETED,1057,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,22.72727273,SGP033297,Batch191,Y,NA,Y,NA,Non-Responder,NA,7.2,SER-401 Active,2,0,7,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0001,C1D1,f__Ruminococcaceae,12094961,10.02085944519919,SGP033303,Ship_6425,Stool - OmniGut Aliquot,A297BS036-002,BK01561ST01-A1,3/12/19,PICI0014-102-S0001,Y,Y,102,MD Anderson Cancer Center,72,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Active,2/26/19,PROGRESSIVE DISEASE,188,COMPLETED,1057,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,22.72727273,SGP033303,Batch191,Y,NA,Y,NA,Non-Responder,NA,7.2,SER-401 Active,2,0,7,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0001,C1D8,f__Ruminococcaceae,14241161,12.5616405195325,SGP033304,Ship_6425,Stool - OmniGut Aliquot,A297BS039-002,BK01559ST01-A1,3/19/19,PICI0014-102-S0001,Y,Y,102,MD Anderson Cancer Center,72,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Active,2/26/19,PROGRESSIVE DISEASE,188,COMPLETED,1057,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,22.72727273,SGP033304,Batch191,Y,NA,Y,NA,Non-Responder,NA,7.2,SER-401 Active,2,0,7,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0001,C2D1,f__Ruminococcaceae,18734845,13.873721490071786,SGP033305,Ship_6425,Stool - OmniGut Aliquot,A580BS223-002,BK01569ST01-A1,4/9/19,PICI0014-102-S0001,Y,Y,102,MD Anderson Cancer Center,72,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Active,2/26/19,PROGRESSIVE DISEASE,188,COMPLETED,1057,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,22.72727273,SGP033305,Batch191,Y,NA,Y,NA,Non-Responder,NA,7.2,SER-401 Active,2,0,7,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0001,C3D1,f__Ruminococcaceae,14416855,14.642030987630717,SGP033309,Ship_6425,Stool - OmniGut Aliquot,A054BT447-002,BK01560ST01-A1,5/7/19,PICI0014-102-S0001,Y,Y,102,MD Anderson Cancer Center,72,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Active,2/26/19,PROGRESSIVE DISEASE,188,COMPLETED,1057,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,22.72727273,SGP033309,Batch191,Y,NA,Y,NA,Non-Responder,NA,7.2,SER-401 Active,2,0,7,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0001,C4D1,f__Ruminococcaceae,14389494,13.633851289776894,SGP033316,Ship_6425,Stool - OmniGut Aliquot,A530BT285-002,BK01574ST01-A1,6/4/19,PICI0014-102-S0001,Y,Y,102,MD Anderson Cancer Center,72,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Active,2/26/19,PROGRESSIVE DISEASE,188,COMPLETED,1057,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,22.72727273,SGP033316,Batch191,Y,NA,Y,NA,Non-Responder,NA,7.2,SER-401 Active,2,0,7,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0001,C7D1,f__Ruminococcaceae,47867535,19.874381792169068,SGP033328,Ship_6425,Stool - OmniGut Aliquot,A807BU719-002,BK04451ST01-A1,9/3/19,PICI0014-102-S0001,Y,Y,102,MD Anderson Cancer Center,72,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Active,2/26/19,PROGRESSIVE DISEASE,188,COMPLETED,1057,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,22.72727273,SGP033328,Batch191,Y,NA,Y,NA,Non-Responder,NA,7.2,SER-401 Active,2,0,7,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0001,D-7,f__Ruminococcaceae,5137,0.005150939782295235,SGP033302,Ship_6425,Stool - OmniGut Aliquot,A506BS663-002,BK01570ST01-A1,3/5/19,PICI0014-102-S0001,Y,Y,102,MD Anderson Cancer Center,72,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Active,2/26/19,PROGRESSIVE DISEASE,188,COMPLETED,1057,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,22.72727273,SGP033302,Batch191,Y,NA,Y,NA,Non-Responder,NA,7.2,SER-401 Active,2,0,7,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0002,BL,f__Ruminococcaceae,7045191,8.088985243243487,SGP033301,Ship_6425,Stool - OmniGut Aliquot,A233BT406-001,BK01549ST02-01,4/23/19,PICI0014-102-S0002,Y,Y,102,MD Anderson Cancer Center,60,Male,Other,Hispanic or Latino,IIC,IV,Cutaneous,Unknown,BRAF V600E,Low,SER-401 Active,4/30/19,PROGRESSIVE DISEASE,69,DEATH,295,PROGRESSIVE DISEASE,295,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,150.9090909,SGP033301,Batch191,Y,NA,Y,NA,Non-Responder,NA,24.8,SER-401 Active,2,0,10,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0002,C1D1,f__Ruminococcaceae,3050547,3.6853860776583027,SGP033311,Ship_6425,Stool - OmniGut Aliquot,A188BT874-002,BK01572ST01-A1,5/14/19,PICI0014-102-S0002,Y,Y,102,MD Anderson Cancer Center,60,Male,Other,Hispanic or Latino,IIC,IV,Cutaneous,Unknown,BRAF V600E,Low,SER-401 Active,4/30/19,PROGRESSIVE DISEASE,69,DEATH,295,PROGRESSIVE DISEASE,295,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,150.9090909,SGP033311,Batch191,Y,NA,Y,NA,Non-Responder,NA,24.8,SER-401 Active,2,0,10,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0002,C1D8,f__Ruminococcaceae,9942616,8.459887620478817,SGP033312,Ship_6425,Stool - OmniGut Aliquot,A303BT433-002,BK04441ST01-A1,5/21/19,PICI0014-102-S0002,Y,Y,102,MD Anderson Cancer Center,60,Male,Other,Hispanic or Latino,IIC,IV,Cutaneous,Unknown,BRAF V600E,Low,SER-401 Active,4/30/19,PROGRESSIVE DISEASE,69,DEATH,295,PROGRESSIVE DISEASE,295,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,150.9090909,SGP033312,Batch191,Y,NA,Y,NA,Non-Responder,NA,24.8,SER-401 Active,2,0,10,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0002,C2D1,f__Ruminococcaceae,20205956,17.60749520792492,SGP033318,Ship_6425,Stool - OmniGut Aliquot,A617BT181-002,BK01573ST01-A1,6/11/19,PICI0014-102-S0002,Y,Y,102,MD Anderson Cancer Center,60,Male,Other,Hispanic or Latino,IIC,IV,Cutaneous,Unknown,BRAF V600E,Low,SER-401 Active,4/30/19,PROGRESSIVE DISEASE,69,DEATH,295,PROGRESSIVE DISEASE,295,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,150.9090909,SGP033318,Batch191,Y,NA,Y,NA,Non-Responder,NA,24.8,SER-401 Active,2,0,10,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0002,D-7,f__Ruminococcaceae,0,0,SGP033310,Ship_6425,Stool - OmniGut Aliquot,A054BT435-002,BK01568ST01-A1,5/7/19,PICI0014-102-S0002,Y,Y,102,MD Anderson Cancer Center,60,Male,Other,Hispanic or Latino,IIC,IV,Cutaneous,Unknown,BRAF V600E,Low,SER-401 Active,4/30/19,PROGRESSIVE DISEASE,69,DEATH,295,PROGRESSIVE DISEASE,295,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,150.9090909,SGP033310,Batch191,Y,NA,Y,NA,Non-Responder,NA,24.8,SER-401 Active,2,0,10,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0002,EOT,f__Ruminococcaceae,13220402,20.351019786762585,SGP033321,Ship_6425,Stool - OmniGut Aliquot,A011BU982-002,BK04442ST01-A1,7/9/19,PICI0014-102-S0002,Y,Y,102,MD Anderson Cancer Center,60,Male,Other,Hispanic or Latino,IIC,IV,Cutaneous,Unknown,BRAF V600E,Low,SER-401 Active,4/30/19,PROGRESSIVE DISEASE,69,DEATH,295,PROGRESSIVE DISEASE,295,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,150.9090909,SGP033321,Batch191,Y,NA,Y,NA,Non-Responder,NA,24.8,SER-401 Active,2,0,10,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0003,BL,f__Ruminococcaceae,9190470,8.989535278194332,SGP033300,Ship_6425,Stool - OmniGut Aliquot,A282BV165-001,BK01548ST02-1,5/14/19,PICI0014-102-S0003,Y,Y,102,MD Anderson Cancer Center,26,Male,White,Not Hispanic or Latino,NA,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Placebo,5/21/19,COMPLETED,336,LOST TO FOLLOW-UP,532,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-52.74725275,SGP033300,Batch191,Y,NA,Y,NA,Responder,19,81.7,SER-401 Placebo,14,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0003,C1D1,f__Ruminococcaceae,20284743,17.73604651213625,SGP033315,Ship_6425,Stool - OmniGut Aliquot,A530BT278-002,BK01577ST01-A1,6/4/19,PICI0014-102-S0003,Y,Y,102,MD Anderson Cancer Center,26,Male,White,Not Hispanic or Latino,NA,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Placebo,5/21/19,COMPLETED,336,LOST TO FOLLOW-UP,532,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-52.74725275,SGP033315,Batch191,Y,NA,Y,NA,Responder,19,81.7,SER-401 Placebo,14,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0003,C1D8,f__Ruminococcaceae,11193150,9.671469684159332,SGP033317,Ship_6425,Stool - OmniGut Aliquot,A617BT188-002,BK01571ST01-A1,6/11/19,PICI0014-102-S0003,Y,Y,102,MD Anderson Cancer Center,26,Male,White,Not Hispanic or Latino,NA,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Placebo,5/21/19,COMPLETED,336,LOST TO FOLLOW-UP,532,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-52.74725275,SGP033317,Batch191,Y,NA,Y,NA,Responder,19,81.7,SER-401 Placebo,14,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0003,C2D1,f__Ruminococcaceae,12258475,12.53295511407824,SGP033320,Ship_6425,Stool - OmniGut Aliquot,A949BT689-002,BK01576ST01-A1,7/2/19,PICI0014-102-S0003,Y,Y,102,MD Anderson Cancer Center,26,Male,White,Not Hispanic or Latino,NA,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Placebo,5/21/19,COMPLETED,336,LOST TO FOLLOW-UP,532,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-52.74725275,SGP033320,Batch191,Y,NA,Y,NA,Responder,19,81.7,SER-401 Placebo,14,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0003,C3D1,f__Ruminococcaceae,4317133,6.634579058455757,SGP033323,Ship_6425,Stool - OmniGut Aliquot,A295BU755-002,BK01578ST01-A1,7/30/19,PICI0014-102-S0003,Y,Y,102,MD Anderson Cancer Center,26,Male,White,Not Hispanic or Latino,NA,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Placebo,5/21/19,COMPLETED,336,LOST TO FOLLOW-UP,532,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-52.74725275,SGP033323,Batch191,Y,NA,Y,NA,Responder,19,81.7,SER-401 Placebo,14,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0003,C4D1,f__Ruminococcaceae,7436402,7.038724284098639,SGP033327,Ship_6425,Stool - OmniGut Aliquot,A715BU031-002,BK04450ST01-A1,8/27/19,PICI0014-102-S0003,Y,Y,102,MD Anderson Cancer Center,26,Male,White,Not Hispanic or Latino,NA,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Placebo,5/21/19,COMPLETED,336,LOST TO FOLLOW-UP,532,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-52.74725275,SGP033327,Batch191,Y,NA,Y,NA,Responder,19,81.7,SER-401 Placebo,14,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0003,C7D1,f__Ruminococcaceae,7075862,5.434134573806514,SGP033340,Ship_6425,Stool - OmniGut Aliquot,A818BV880-002,10796669-A01-A1,11/19/19,PICI0014-102-S0003,Y,Y,102,MD Anderson Cancer Center,26,Male,White,Not Hispanic or Latino,NA,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Placebo,5/21/19,COMPLETED,336,LOST TO FOLLOW-UP,532,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-52.74725275,SGP033340,Batch191,Y,NA,Y,NA,Responder,19,81.7,SER-401 Placebo,14,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0003,D-7,f__Ruminococcaceae,11122899,11.691153108596842,SGP033313,Ship_6425,Stool - OmniGut Aliquot,A420BT084-002,BK04440ST01-A1,5/28/19,PICI0014-102-S0003,Y,Y,102,MD Anderson Cancer Center,26,Male,White,Not Hispanic or Latino,NA,IV,Cutaneous,Unknown,Unknown,Low,SER-401 Placebo,5/21/19,COMPLETED,336,LOST TO FOLLOW-UP,532,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-52.74725275,SGP033313,Batch191,Y,NA,Y,NA,Responder,19,81.7,SER-401 Placebo,14,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0005,BL,f__Ruminococcaceae,25929493,19.458718118934794,SGP033298,Ship_6425,Stool - OmniGut Aliquot,A281BV490-001,BK01541ST02-01,6/18/19,PICI0014-102-S0005,Y,Y,102,MD Anderson Cancer Center,78,Male,White,Not Hispanic or Latino,IIIB,IIIC,Cutaneous,NRAS – other mutation,BRAF V600E,High,SER-401 Active,7/25/19,PROGRESSIVE DISEASE,123,DEATH,300,PASSED IN HOSPICE,300,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,60,SGP033298,Batch191,Y,NA,Y,NA,Non-Responder,17.3,NA,SER-401 Active,2,0,10,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0005,C1D1,f__Ruminococcaceae,12693209,11.218697351353626,SGP033325,Ship_6425,Stool - OmniGut Aliquot,A406BU146-002,BK01575ST01-A1,8/8/19,PICI0014-102-S0005,Y,Y,102,MD Anderson Cancer Center,78,Male,White,Not Hispanic or Latino,IIIB,IIIC,Cutaneous,NRAS – other mutation,BRAF V600E,High,SER-401 Active,7/25/19,PROGRESSIVE DISEASE,123,DEATH,300,PASSED IN HOSPICE,300,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,60,SGP033325,Batch191,Y,NA,Y,NA,Non-Responder,17.3,NA,SER-401 Active,2,0,10,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0005,C1D8,f__Ruminococcaceae,29102633,18.671839517291286,SGP033326,Ship_6425,Stool - OmniGut Aliquot,A502BU238-002,BK04449ST01-A1,8/15/19,PICI0014-102-S0005,Y,Y,102,MD Anderson Cancer Center,78,Male,White,Not Hispanic or Latino,IIIB,IIIC,Cutaneous,NRAS – other mutation,BRAF V600E,High,SER-401 Active,7/25/19,PROGRESSIVE DISEASE,123,DEATH,300,PASSED IN HOSPICE,300,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,60,SGP033326,Batch191,Y,NA,Y,NA,Non-Responder,17.3,NA,SER-401 Active,2,0,10,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0005,C2D1,f__Ruminococcaceae,25738402,16.737814925461343,SGP033329,Ship_6425,Stool - OmniGut Aliquot,A016BV445-002,BK04446ST01-A1,9/5/19,PICI0014-102-S0005,Y,Y,102,MD Anderson Cancer Center,78,Male,White,Not Hispanic or Latino,IIIB,IIIC,Cutaneous,NRAS – other mutation,BRAF V600E,High,SER-401 Active,7/25/19,PROGRESSIVE DISEASE,123,DEATH,300,PASSED IN HOSPICE,300,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,60,SGP033329,Batch191,Y,NA,Y,NA,Non-Responder,17.3,NA,SER-401 Active,2,0,10,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0005,C3D1,f__Ruminococcaceae,21457369,15.665767268845912,SGP033331,Ship_6425,Stool - OmniGut Aliquot,A193BV558-002,BK04445ST01-A1,10/3/19,PICI0014-102-S0005,Y,Y,102,MD Anderson Cancer Center,78,Male,White,Not Hispanic or Latino,IIIB,IIIC,Cutaneous,NRAS – other mutation,BRAF V600E,High,SER-401 Active,7/25/19,PROGRESSIVE DISEASE,123,DEATH,300,PASSED IN HOSPICE,300,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,60,SGP033331,Batch191,Y,NA,Y,NA,Non-Responder,17.3,NA,SER-401 Active,2,0,10,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0005,C4D1,f__Ruminococcaceae,22253999,16.44066841463471,SGP033337,Ship_6425,Stool - OmniGut Aliquot,A550BV905-002,BK04447ST01-A1,10/31/19,PICI0014-102-S0005,Y,Y,102,MD Anderson Cancer Center,78,Male,White,Not Hispanic or Latino,IIIB,IIIC,Cutaneous,NRAS – other mutation,BRAF V600E,High,SER-401 Active,7/25/19,PROGRESSIVE DISEASE,123,DEATH,300,PASSED IN HOSPICE,300,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,60,SGP033337,Batch191,Y,NA,Y,NA,Non-Responder,17.3,NA,SER-401 Active,2,0,10,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0005,D-7,f__Ruminococcaceae,171699,0.12533505423185215,SGP033324,Ship_6425,Stool - OmniGut Aliquot,A313BU288-002,BK04443ST01-A1,8/1/19,PICI0014-102-S0005,Y,Y,102,MD Anderson Cancer Center,78,Male,White,Not Hispanic or Latino,IIIB,IIIC,Cutaneous,NRAS – other mutation,BRAF V600E,High,SER-401 Active,7/25/19,PROGRESSIVE DISEASE,123,DEATH,300,PASSED IN HOSPICE,300,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,60,SGP033324,Batch191,Y,NA,Y,NA,Non-Responder,17.3,NA,SER-401 Active,2,0,10,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0006,BL,f__Ruminococcaceae,6392348,6.010949412753186,SGP033299,Ship_6425,Stool - OmniGut Aliquot,A281BV520-001,BK01525ST02-01,9/10/19,PICI0014-102-S0006,Y,Y,102,MD Anderson Cancer Center,46,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,BRAF V600E,Low,SER-401 Active,9/20/19,PROGRESSIVE DISEASE,129,DEATH,399,UNKNOWN,399,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-48.8372093,SGP033299,Batch191,Y,NA,Y,NA,Non-Responder,23.2,59.8,SER-401 Active,5,0,13,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0006,C1D1,f__Ruminococcaceae,14325378,14.614276376698134,SGP033332,Ship_6425,Stool - OmniGut Aliquot,A243BV637-002,BK04444ST01-A1,10/8/19,PICI0014-102-S0006,Y,Y,102,MD Anderson Cancer Center,46,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,BRAF V600E,Low,SER-401 Active,9/20/19,PROGRESSIVE DISEASE,129,DEATH,399,UNKNOWN,399,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-48.8372093,SGP033332,Batch191,Y,NA,Y,NA,Non-Responder,23.2,59.8,SER-401 Active,5,0,13,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0006,C1D8,f__Ruminococcaceae,13586309,22.64089746969645,SGP033333,Ship_6425,Stool - OmniGut Aliquot,A382BV635-002,10796671-A01-A1,10/17/19,PICI0014-102-S0006,Y,Y,102,MD Anderson Cancer Center,46,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,BRAF V600E,Low,SER-401 Active,9/20/19,PROGRESSIVE DISEASE,129,DEATH,399,UNKNOWN,399,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-48.8372093,SGP033333,Batch191,Y,NA,Y,NA,Non-Responder,23.2,59.8,SER-401 Active,5,0,13,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0006,C2D1,f__Ruminococcaceae,15238056,11.16886630515969,SGP033338,Ship_6425,Stool - OmniGut Aliquot,A616BV971-002,10796675-A01-A1,11/5/19,PICI0014-102-S0006,Y,Y,102,MD Anderson Cancer Center,46,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,BRAF V600E,Low,SER-401 Active,9/20/19,PROGRESSIVE DISEASE,129,DEATH,399,UNKNOWN,399,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-48.8372093,SGP033338,Batch191,Y,NA,Y,NA,Non-Responder,23.2,59.8,SER-401 Active,5,0,13,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0006,C3D1,f__Ruminococcaceae,13499134,8.020778261835401,SGP033344,Ship_6425,Stool - OmniGut Aliquot,A013BW184-002,10796676-A01-A1,12/3/19,PICI0014-102-S0006,Y,Y,102,MD Anderson Cancer Center,46,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,BRAF V600E,Low,SER-401 Active,9/20/19,PROGRESSIVE DISEASE,129,DEATH,399,UNKNOWN,399,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-48.8372093,SGP033344,Batch191,Y,NA,Y,NA,Non-Responder,23.2,59.8,SER-401 Active,5,0,13,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0006,C4D1,f__Ruminococcaceae,6265276,9.332753183907617,SGP033346,Ship_6425,Stool - OmniGut Aliquot,A379BW785-002,10796674-A01-A1,1/3/20,PICI0014-102-S0006,Y,Y,102,MD Anderson Cancer Center,46,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,BRAF V600E,Low,SER-401 Active,9/20/19,PROGRESSIVE DISEASE,129,DEATH,399,UNKNOWN,399,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-48.8372093,SGP033346,Batch191,Y,NA,Y,NA,Non-Responder,23.2,59.8,SER-401 Active,5,0,13,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0006,D-7,f__Ruminococcaceae,0,0,SGP033330,Ship_6425,Stool - OmniGut Aliquot,A178BV355-002,BK04448ST01-A1,10/1/19,PICI0014-102-S0006,Y,Y,102,MD Anderson Cancer Center,46,Male,White,Not Hispanic or Latino,IIIC,IV,Cutaneous,Unknown,BRAF V600E,Low,SER-401 Active,9/20/19,PROGRESSIVE DISEASE,129,DEATH,399,UNKNOWN,399,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-48.8372093,SGP033330,Batch191,Y,NA,Y,NA,Non-Responder,23.2,59.8,SER-401 Active,5,0,13,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Progressive Disease,NA,NA,PD
102-S0009,BL,f__Ruminococcaceae,9157897,12.971098515114035,SGP039576,Ship_7129,Stool - OmniGut Aliquot,A139CH285-001,10820865-A02-1,9/14/20,PICI0014-102-S0009,Y,Y,102,MD Anderson Cancer Center,73,Male,White,Not Hispanic or Latino,IIIA,IIIA,Acral,NRAS – other mutation,BRAF – other mutation,Low,SER-401 Placebo,9/21/20,COMPLETED,322,COMPLETED,484,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-72.09302326,SGP039576,Batch234,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,10,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0009,C1D1,f__Ruminococcaceae,6007094,7.586302405917683,SGP039585,Ship_7129,Stool - OmniGut Aliquot,A706CB536-002,10830984-A01-A1,10/5/20,PICI0014-102-S0009,Y,Y,102,MD Anderson Cancer Center,73,Male,White,Not Hispanic or Latino,IIIA,IIIA,Acral,NRAS – other mutation,BRAF – other mutation,Low,SER-401 Placebo,9/21/20,COMPLETED,322,COMPLETED,484,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-72.09302326,SGP039585,Batch234,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,10,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0009,C1D8,f__Ruminococcaceae,10125436,11.67167351254327,SGP039604,Ship_7129,Stool - OmniGut Aliquot,A847CB690-002,10830981-A01-A1,44117,PICI0014-102-S0009,Y,Y,102,MD Anderson Cancer Center,73,Male,White,Not Hispanic or Latino,IIIA,IIIA,Acral,NRAS – other mutation,BRAF – other mutation,Low,SER-401 Placebo,9/21/20,COMPLETED,322,COMPLETED,484,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-72.09302326,SGP039604,Batch234,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,10,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0009,C2D1,f__Ruminococcaceae,10870525,11.10579346040322,SGP039606,Ship_7129,Stool - OmniGut Aliquot,A130CC926-002,10830978-A01-A1,11/2/20,PICI0014-102-S0009,Y,Y,102,MD Anderson Cancer Center,73,Male,White,Not Hispanic or Latino,IIIA,IIIA,Acral,NRAS – other mutation,BRAF – other mutation,Low,SER-401 Placebo,9/21/20,COMPLETED,322,COMPLETED,484,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-72.09302326,SGP039606,Batch234,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,10,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0009,C3D1,f__Ruminococcaceae,6699641,11.714407240912735,SGP039607,Ship_7129,Stool - OmniGut Aliquot,A525CC869-002,10830979-A01-A1,11/30/20,PICI0014-102-S0009,Y,Y,102,MD Anderson Cancer Center,73,Male,White,Not Hispanic or Latino,IIIA,IIIA,Acral,NRAS – other mutation,BRAF – other mutation,Low,SER-401 Placebo,9/21/20,COMPLETED,322,COMPLETED,484,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-72.09302326,SGP039607,Batch234,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,10,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0009,C4D1,f__Ruminococcaceae,8939138,13.58565595729036,SGP039609,Ship_7129,Stool - OmniGut Aliquot,A977CC369-002,10909809-A01-A1,12/27/20,PICI0014-102-S0009,Y,Y,102,MD Anderson Cancer Center,73,Male,White,Not Hispanic or Latino,IIIA,IIIA,Acral,NRAS – other mutation,BRAF – other mutation,Low,SER-401 Placebo,9/21/20,COMPLETED,322,COMPLETED,484,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-72.09302326,SGP039609,Batch234,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,10,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0009,C7D1,f__Ruminococcaceae,6497318,8.665988342075234,SGP039612,Ship_7129,Stool - OmniGut Aliquot,A041CI809-002,10909807-A01-A1,3/22/21,PICI0014-102-S0009,Y,Y,102,MD Anderson Cancer Center,73,Male,White,Not Hispanic or Latino,IIIA,IIIA,Acral,NRAS – other mutation,BRAF – other mutation,Low,SER-401 Placebo,9/21/20,COMPLETED,322,COMPLETED,484,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-72.09302326,SGP039612,Batch234,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,10,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
102-S0009,D-7,f__Ruminococcaceae,10212916,14.69805622400304,SGP039583,Ship_7129,Stool - OmniGut Aliquot,A612CB199-002,10830980-A01-A1,9/28/20,PICI0014-102-S0009,Y,Y,102,MD Anderson Cancer Center,73,Male,White,Not Hispanic or Latino,IIIA,IIIA,Acral,NRAS – other mutation,BRAF – other mutation,Low,SER-401 Placebo,9/21/20,COMPLETED,322,COMPLETED,484,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-72.09302326,SGP039583,Batch234,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,10,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
107-S0002,BL,f__Ruminococcaceae,5924758,8.231295714298437,SGP033358,Ship_6425,Stool - OmniGut Aliquot,A882BZ424-001,10767797-A01-01,11/5/19,PICI0014-107-S0002,Y,Y,107,Dana-Farber Cancer Institute- Boston,64,Male,White,Not Hispanic or Latino,IV,IV,Cutaneous,Wild Type,BRAF V600K,Low,SER-401 Active,11/6/19,PHYSICIAN DECISION,71,COMPLETED,806,NA,NA,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-20,SGP033358,Batch191,Y,NA,Y,NA,Non-Responder,11,28.5,SER-401 Active,3,1,3,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease < 24 weeks,SD
107-S0002,C1D1,f__Ruminococcaceae,6122191,8.478596318412517,SGP033341,Ship_6425,Stool - OmniGut Aliquot,A838BV958-002,10767801-A01-A1,11/20/19,PICI0014-107-S0002,Y,Y,107,Dana-Farber Cancer Institute- Boston,64,Male,White,Not Hispanic or Latino,IV,IV,Cutaneous,Wild Type,BRAF V600K,Low,SER-401 Active,11/6/19,PHYSICIAN DECISION,71,COMPLETED,806,NA,NA,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-20,SGP033341,Batch191,Y,NA,Y,NA,Non-Responder,11,28.5,SER-401 Active,3,1,3,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease < 24 weeks,SD
107-S0002,C1D8,f__Ruminococcaceae,7868863,11.866844239611515,SGP033343,Ship_6425,Stool - OmniGut Aliquot,A945BV968-002,10767799-A01-A1,11/26/19,PICI0014-107-S0002,Y,Y,107,Dana-Farber Cancer Institute- Boston,64,Male,White,Not Hispanic or Latino,IV,IV,Cutaneous,Wild Type,BRAF V600K,Low,SER-401 Active,11/6/19,PHYSICIAN DECISION,71,COMPLETED,806,NA,NA,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-20,SGP033343,Batch191,Y,NA,Y,NA,Non-Responder,11,28.5,SER-401 Active,3,1,3,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease < 24 weeks,SD
107-S0002,C2D1,f__Ruminococcaceae,14778092,15.324071028047657,SGP033345,Ship_6425,Stool - OmniGut Aliquot,A379BW730-002,10827440-A01-A1,12/19/19,PICI0014-107-S0002,Y,Y,107,Dana-Farber Cancer Institute- Boston,64,Male,White,Not Hispanic or Latino,IV,IV,Cutaneous,Wild Type,BRAF V600K,Low,SER-401 Active,11/6/19,PHYSICIAN DECISION,71,COMPLETED,806,NA,NA,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-20,SGP033345,Batch191,Y,NA,Y,NA,Non-Responder,11,28.5,SER-401 Active,3,1,3,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease < 24 weeks,SD
107-S0002,C3D1,f__Ruminococcaceae,29542922,24.24503114242793,SGP033349,Ship_6425,Stool - OmniGut Aliquot,A846BW659-002,10827445-A01-A1,1/16/20,PICI0014-107-S0002,Y,Y,107,Dana-Farber Cancer Institute- Boston,64,Male,White,Not Hispanic or Latino,IV,IV,Cutaneous,Wild Type,BRAF V600K,Low,SER-401 Active,11/6/19,PHYSICIAN DECISION,71,COMPLETED,806,NA,NA,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-20,SGP033349,Batch191,Y,NA,Y,NA,Non-Responder,11,28.5,SER-401 Active,3,1,3,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease < 24 weeks,SD
107-S0002,D-7,f__Ruminococcaceae,0,0,SGP033339,Ship_6425,Stool - OmniGut Aliquot,A709BV712-002,10767800-A01-A1,11/11/19,PICI0014-107-S0002,Y,Y,107,Dana-Farber Cancer Institute- Boston,64,Male,White,Not Hispanic or Latino,IV,IV,Cutaneous,Wild Type,BRAF V600K,Low,SER-401 Active,11/6/19,PHYSICIAN DECISION,71,COMPLETED,806,NA,NA,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-20,SGP033339,Batch191,Y,NA,Y,NA,Non-Responder,11,28.5,SER-401 Active,3,1,3,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease < 24 weeks,SD
107-S0002,EOT,f__Ruminococcaceae,15556689,15.521916492235762,SGP033351,Ship_6425,Stool - OmniGut Aliquot,A053BX587-002,10827436-A01-A1,2/12/20,PICI0014-107-S0002,Y,Y,107,Dana-Farber Cancer Institute- Boston,64,Male,White,Not Hispanic or Latino,IV,IV,Cutaneous,Wild Type,BRAF V600K,Low,SER-401 Active,11/6/19,PHYSICIAN DECISION,71,COMPLETED,806,NA,NA,STABLE DISEASE,SD < 24 weeks,Non-responder,Non-responder,-20,SGP033351,Batch191,Y,NA,Y,NA,Non-Responder,11,28.5,SER-401 Active,3,1,3,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease < 24 weeks,SD
107-S0003,BL,f__Ruminococcaceae,8093939,6.288815850328473,SGP033359,Ship_6425,Stool - OmniGut Aliquot,A882BZ437-001,107-S0003-omni1-1,12/29/19,PICI0014-107-S0003,Y,Y,107,Dana-Farber Cancer Institute- Boston,55,Female,White,Not Hispanic or Latino,IIIB,IIIB,Cutaneous,Wild Type,BRAF V600E,Low,SER-401 Placebo,1/17/20,COMPLETED,340,COMPLETED,733,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-54.33789954,SGP033359,Batch191,Y,NA,Y,NA,Responder,19.9,NA,SER-401 Placebo,18,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
107-S0003,C1D1,f__Ruminococcaceae,9976514,12.889566127593335,SGP033352,Ship_6425,Stool - OmniGut Aliquot,A053BX579-002,22001906603612-A1,43861,PICI0014-107-S0003,Y,Y,107,Dana-Farber Cancer Institute- Boston,55,Female,White,Not Hispanic or Latino,IIIB,IIIB,Cutaneous,Wild Type,BRAF V600E,Low,SER-401 Placebo,1/17/20,COMPLETED,340,COMPLETED,733,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-54.33789954,SGP033352,Batch191,Y,NA,Y,NA,Responder,19.9,NA,SER-401 Placebo,18,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
107-S0003,C1D8,f__Ruminococcaceae,12611806,9.463020689488754,SGP033353,Ship_6425,Stool - OmniGut Aliquot,A053BX575-002,22001906603560-A1,43871,PICI0014-107-S0003,Y,Y,107,Dana-Farber Cancer Institute- Boston,55,Female,White,Not Hispanic or Latino,IIIB,IIIB,Cutaneous,Wild Type,BRAF V600E,Low,SER-401 Placebo,1/17/20,COMPLETED,340,COMPLETED,733,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-54.33789954,SGP033353,Batch191,Y,NA,Y,NA,Responder,19.9,NA,SER-401 Placebo,18,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
107-S0003,C2D1,f__Ruminococcaceae,10314024,11.621362949463956,SGP033360,Ship_6425,Stool - OmniGut Aliquot,A331BX047-002,22001906602849-A1,2/29/20,PICI0014-107-S0003,Y,Y,107,Dana-Farber Cancer Institute- Boston,55,Female,White,Not Hispanic or Latino,IIIB,IIIB,Cutaneous,Wild Type,BRAF V600E,Low,SER-401 Placebo,1/17/20,COMPLETED,340,COMPLETED,733,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-54.33789954,SGP033360,Batch191,Y,NA,Y,NA,Responder,19.9,NA,SER-401 Placebo,18,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
107-S0003,C3D1,f__Ruminococcaceae,9286566,12.596823531374637,SGP039587,Ship_7129,Stool - OmniGut Aliquot,A628BY791-002,10841291-A01-A1,3/25/20,PICI0014-107-S0003,Y,Y,107,Dana-Farber Cancer Institute- Boston,55,Female,White,Not Hispanic or Latino,IIIB,IIIB,Cutaneous,Wild Type,BRAF V600E,Low,SER-401 Placebo,1/17/20,COMPLETED,340,COMPLETED,733,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-54.33789954,SGP039587,Batch234,Y,NA,Y,NA,Responder,19.9,NA,SER-401 Placebo,18,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
107-S0003,C4D1,f__Ruminococcaceae,2285335,3.3206692709102987,SGP039589,Ship_7129,Stool - OmniGut Aliquot,A092BZ297-002,22001906603641-A1,4/25/20,PICI0014-107-S0003,Y,Y,107,Dana-Farber Cancer Institute- Boston,55,Female,White,Not Hispanic or Latino,IIIB,IIIB,Cutaneous,Wild Type,BRAF V600E,Low,SER-401 Placebo,1/17/20,COMPLETED,340,COMPLETED,733,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-54.33789954,SGP039589,Batch234,Y,NA,Y,NA,Responder,19.9,NA,SER-401 Placebo,18,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
107-S0003,C7D1,f__Ruminococcaceae,9834297,13.066274316483694,SGP039595,Ship_7129,Stool - OmniGut Aliquot,A564CA280-002,10841293-A01-A1,7/17/20,PICI0014-107-S0003,Y,Y,107,Dana-Farber Cancer Institute- Boston,55,Female,White,Not Hispanic or Latino,IIIB,IIIB,Cutaneous,Wild Type,BRAF V600E,Low,SER-401 Placebo,1/17/20,COMPLETED,340,COMPLETED,733,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-54.33789954,SGP039595,Batch234,Y,NA,Y,NA,Responder,19.9,NA,SER-401 Placebo,18,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
107-S0003,D-7,f__Ruminococcaceae,7072337,7.139926183021165,SGP033348,Ship_6425,Stool - OmniGut Aliquot,A846BW651-002,22001906603647-A1,1/23/20,PICI0014-107-S0003,Y,Y,107,Dana-Farber Cancer Institute- Boston,55,Female,White,Not Hispanic or Latino,IIIB,IIIB,Cutaneous,Wild Type,BRAF V600E,Low,SER-401 Placebo,1/17/20,COMPLETED,340,COMPLETED,733,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-54.33789954,SGP033348,Batch191,Y,NA,Y,NA,Responder,19.9,NA,SER-401 Placebo,18,1,12,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
107-S0006,BL,f__Ruminococcaceae,7628594,9.891237148697659,SGP039579,Ship_7129,Stool - OmniGut Aliquot,A138CH897-001,10827431-A01-01,6/30/20,PICI0014-107-S0006,Y,Y,107,Dana-Farber Cancer Institute- Boston,32,Female,White,Not Hispanic or Latino,IV,IV,Mucosal,Unknown,BRAF V600E,Low,SER-401 Placebo,7/7/20,COMPLETED,336,COMPLETED,562,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,-0.483091787,SGP039579,Batch234,Y,NA,Y,NA,Non-Responder,NA,NA,SER-401 Placebo,3,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Progressive Disease,NA,NA,PD
107-S0006,C1D1,f__Ruminococcaceae,7587347,11.516760727295337,SGP039596,Ship_7129,Stool - OmniGut Aliquot,A663CA867-002,10827439-A01-A1,7/17/20,PICI0014-107-S0006,Y,Y,107,Dana-Farber Cancer Institute- Boston,32,Female,White,Not Hispanic or Latino,IV,IV,Mucosal,Unknown,BRAF V600E,Low,SER-401 Placebo,7/7/20,COMPLETED,336,COMPLETED,562,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,-0.483091787,SGP039596,Batch234,Y,NA,Y,NA,Non-Responder,NA,NA,SER-401 Placebo,3,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Progressive Disease,NA,NA,PD
107-S0006,C1D8,f__Ruminococcaceae,6426230,9.310392358577,SGP039598,Ship_7129,Stool - OmniGut Aliquot,A714CA149-002,10827442-A01-A1,7/28/20,PICI0014-107-S0006,Y,Y,107,Dana-Farber Cancer Institute- Boston,32,Female,White,Not Hispanic or Latino,IV,IV,Mucosal,Unknown,BRAF V600E,Low,SER-401 Placebo,7/7/20,COMPLETED,336,COMPLETED,562,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,-0.483091787,SGP039598,Batch234,Y,NA,Y,NA,Non-Responder,NA,NA,SER-401 Placebo,3,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Progressive Disease,NA,NA,PD
107-S0006,C2D1,f__Ruminococcaceae,5915085,7.6034295794997515,SGP039602,Ship_7129,Stool - OmniGut Aliquot,A071CB223-002,10880529-A01-A1,8/22/20,PICI0014-107-S0006,Y,Y,107,Dana-Farber Cancer Institute- Boston,32,Female,White,Not Hispanic or Latino,IV,IV,Mucosal,Unknown,BRAF V600E,Low,SER-401 Placebo,7/7/20,COMPLETED,336,COMPLETED,562,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,-0.483091787,SGP039602,Batch234,Y,NA,Y,NA,Non-Responder,NA,NA,SER-401 Placebo,3,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Progressive Disease,NA,NA,PD
107-S0006,C3D1,f__Ruminococcaceae,14364750,16.00312835689284,SGP039582,Ship_7129,Stool - OmniGut Aliquot,A541CB816-002,10880524-A01-A1,9/22/20,PICI0014-107-S0006,Y,Y,107,Dana-Farber Cancer Institute- Boston,32,Female,White,Not Hispanic or Latino,IV,IV,Mucosal,Unknown,BRAF V600E,Low,SER-401 Placebo,7/7/20,COMPLETED,336,COMPLETED,562,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,-0.483091787,SGP039582,Batch234,Y,NA,Y,NA,Non-Responder,NA,NA,SER-401 Placebo,3,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Progressive Disease,NA,NA,PD
107-S0006,C7D1,f__Ruminococcaceae,4931873,6.381031638841595,SGP039611,Ship_7129,Stool - OmniGut Aliquot,A691CD641-002,10880525-A01-A1,1/26/21,PICI0014-107-S0006,Y,Y,107,Dana-Farber Cancer Institute- Boston,32,Female,White,Not Hispanic or Latino,IV,IV,Mucosal,Unknown,BRAF V600E,Low,SER-401 Placebo,7/7/20,COMPLETED,336,COMPLETED,562,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,-0.483091787,SGP039611,Batch234,Y,NA,Y,NA,Non-Responder,NA,NA,SER-401 Placebo,3,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Progressive Disease,NA,NA,PD
107-S0006,D-7,f__Ruminococcaceae,4068687,4.777987063212558,SGP039594,Ship_7129,Stool - OmniGut Aliquot,A447CA077-002,22001906603554-A1,7/13/20,PICI0014-107-S0006,Y,Y,107,Dana-Farber Cancer Institute- Boston,32,Female,White,Not Hispanic or Latino,IV,IV,Mucosal,Unknown,BRAF V600E,Low,SER-401 Placebo,7/7/20,COMPLETED,336,COMPLETED,562,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,-0.483091787,SGP039594,Batch234,Y,NA,Y,NA,Non-Responder,NA,NA,SER-401 Placebo,3,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Progressive Disease,NA,NA,PD
107-S0006,EOT,f__Ruminococcaceae,16199728,23.84322609564223,SGP039605,Ship_7129,Stool - OmniGut Aliquot,A089CC289-002,22002001680647-A1,10/28/20,PICI0014-107-S0006,Y,Y,107,Dana-Farber Cancer Institute- Boston,32,Female,White,Not Hispanic or Latino,IV,IV,Mucosal,Unknown,BRAF V600E,Low,SER-401 Placebo,7/7/20,COMPLETED,336,COMPLETED,562,NA,NA,PROGRESSIVE DISEASE,NA,Non-responder,Non-responder,-0.483091787,SGP039605,Batch234,Y,NA,Y,NA,Non-Responder,NA,NA,SER-401 Placebo,3,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Progressive Disease,NA,NA,PD
108-S0002,BL,f__Ruminococcaceae,20162363,19.738272593911717,SGP033296,Ship_6425,Stool - OmniGut Aliquot,A124BT653-001,BK01537ST02-01,4/9/19,PICI0014-108-S0002,Y,Y,108,The Angeles Clinic,84,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Active,4/15/19,PROGRESSIVE DISEASE,238,DEATH,643,PROGRESSIVE DISEASE,643,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-7.142857143,SGP033296,Batch191,Y,NA,Y,NA,Responder,7,NA,SER-401 Active,9,0,21,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
108-S0002,C1D1,f__Ruminococcaceae,11210775,14.018390957524963,SGP033307,Ship_6425,Stool - OmniGut Aliquot,A887BS974-002,BK01566ST01-A1,4/29/19,PICI0014-108-S0002,Y,Y,108,The Angeles Clinic,84,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Active,4/15/19,PROGRESSIVE DISEASE,238,DEATH,643,PROGRESSIVE DISEASE,643,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-7.142857143,SGP033307,Batch191,Y,NA,Y,NA,Responder,7,NA,SER-401 Active,9,0,21,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
108-S0002,C1D8,f__Ruminococcaceae,20027885,20.010750794632095,SGP033308,Ship_6425,Stool - OmniGut Aliquot,A023BT424-002,BK01562ST01-A1,5/5/19,PICI0014-108-S0002,Y,Y,108,The Angeles Clinic,84,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Active,4/15/19,PROGRESSIVE DISEASE,238,DEATH,643,PROGRESSIVE DISEASE,643,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-7.142857143,SGP033308,Batch191,Y,NA,Y,NA,Responder,7,NA,SER-401 Active,9,0,21,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
108-S0002,C2D1,f__Ruminococcaceae,11335088,7.86585691877936,SGP033314,Ship_6425,Stool - OmniGut Aliquot,A459BT176-002,BK01523ST02-A1,5/28/19,PICI0014-108-S0002,Y,Y,108,The Angeles Clinic,84,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Active,4/15/19,PROGRESSIVE DISEASE,238,DEATH,643,PROGRESSIVE DISEASE,643,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-7.142857143,SGP033314,Batch191,Y,NA,Y,NA,Responder,7,NA,SER-401 Active,9,0,21,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
108-S0002,C3D1,f__Ruminococcaceae,19181476,19.50212109915786,SGP033319,Ship_6425,Stool - OmniGut Aliquot,A839BT143-002,BK01567ST01-A1,6/23/19,PICI0014-108-S0002,Y,Y,108,The Angeles Clinic,84,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Active,4/15/19,PROGRESSIVE DISEASE,238,DEATH,643,PROGRESSIVE DISEASE,643,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-7.142857143,SGP033319,Batch191,Y,NA,Y,NA,Responder,7,NA,SER-401 Active,9,0,21,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
108-S0002,C4D1,f__Ruminococcaceae,21002937,17.34470306267348,SGP033322,Ship_6425,Stool - OmniGut Aliquot,A169BU490-002,BK01564ST01-A1,7/22/19,PICI0014-108-S0002,Y,Y,108,The Angeles Clinic,84,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Active,4/15/19,PROGRESSIVE DISEASE,238,DEATH,643,PROGRESSIVE DISEASE,643,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-7.142857143,SGP033322,Batch191,Y,NA,Y,NA,Responder,7,NA,SER-401 Active,9,0,21,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
108-S0002,D-7,f__Ruminococcaceae,281398,0.2143012103816865,SGP033306,Ship_6425,Stool - OmniGut Aliquot,A761BS374-002,BK01551ST01-A1,4/21/19,PICI0014-108-S0002,Y,Y,108,The Angeles Clinic,84,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Active,4/15/19,PROGRESSIVE DISEASE,238,DEATH,643,PROGRESSIVE DISEASE,643,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-7.142857143,SGP033306,Batch191,Y,NA,Y,NA,Responder,7,NA,SER-401 Active,9,0,21,0,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
108-S0004,BL,f__Ruminococcaceae,17996518,21.62643433683822,SGP033357,Ship_6425,Stool - OmniGut Aliquot,A882BZ408-001,10785465-A01-01,10/7/19,PICI0014-108-S0004,Y,Y,108,The Angeles Clinic,81,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Placebo,10/14/19,PROGRESSIVE DISEASE,267,DEATH,418,PROGRESSIVE DISEASE,418,PARTIAL RESPONSE,NA,Responder,Responder,-70,SGP033357,Batch191,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,9,0,14,0,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
108-S0004,C1D1,f__Ruminococcaceae,24470079,22.48511879547341,SGP033336,Ship_6425,Stool - OmniGut Aliquot,A516BV243-002,10785470-A01-A1,10/29/19,PICI0014-108-S0004,Y,Y,108,The Angeles Clinic,81,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Placebo,10/14/19,PROGRESSIVE DISEASE,267,DEATH,418,PROGRESSIVE DISEASE,418,PARTIAL RESPONSE,NA,Responder,Responder,-70,SGP033336,Batch191,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,9,0,14,0,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
108-S0004,C2D1,f__Ruminococcaceae,31761329,22.510060250588005,SGP033342,Ship_6425,Stool - OmniGut Aliquot,A945BV927-002,BK01563ST01-A2,11/24/19,PICI0014-108-S0004,Y,Y,108,The Angeles Clinic,81,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Placebo,10/14/19,PROGRESSIVE DISEASE,267,DEATH,418,PROGRESSIVE DISEASE,418,PARTIAL RESPONSE,NA,Responder,Responder,-70,SGP033342,Batch191,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,9,0,14,0,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
108-S0004,C3D1,f__Ruminococcaceae,18879340,19.41746574268525,SGP033347,Ship_6425,Stool - OmniGut Aliquot,A411BW669-002,BK01544ST02-A1,12/23/19,PICI0014-108-S0004,Y,Y,108,The Angeles Clinic,81,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Placebo,10/14/19,PROGRESSIVE DISEASE,267,DEATH,418,PROGRESSIVE DISEASE,418,PARTIAL RESPONSE,NA,Responder,Responder,-70,SGP033347,Batch191,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,9,0,14,0,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
108-S0004,C4D1,f__Ruminococcaceae,11941938,20.315026074629547,SGP033350,Ship_6425,Stool - OmniGut Aliquot,A846BW668-002,10827412-A01-A1,43850,PICI0014-108-S0004,Y,Y,108,The Angeles Clinic,81,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Placebo,10/14/19,PROGRESSIVE DISEASE,267,DEATH,418,PROGRESSIVE DISEASE,418,PARTIAL RESPONSE,NA,Responder,Responder,-70,SGP033350,Batch191,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,9,0,14,0,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
108-S0004,C7D1,f__Ruminococcaceae,11367605,17.349030111563877,SGP039588,Ship_7129,Stool - OmniGut Aliquot,A870BY840-002,10827410-A01-A1,43932,PICI0014-108-S0004,Y,Y,108,The Angeles Clinic,81,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Placebo,10/14/19,PROGRESSIVE DISEASE,267,DEATH,418,PROGRESSIVE DISEASE,418,PARTIAL RESPONSE,NA,Responder,Responder,-70,SGP039588,Batch234,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,9,0,14,0,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
108-S0004,D-7,f__Ruminococcaceae,32387881,24.184584915340647,SGP033334,Ship_6425,Stool - OmniGut Aliquot,A438BV542-002,10785468-A01-A1,10/22/19,PICI0014-108-S0004,Y,Y,108,The Angeles Clinic,81,Male,White,Not Hispanic or Latino,IIC,IV,NA,Unknown,BRAF V600E,High,SER-401 Placebo,10/14/19,PROGRESSIVE DISEASE,267,DEATH,418,PROGRESSIVE DISEASE,418,PARTIAL RESPONSE,NA,Responder,Responder,-70,SGP033334,Batch191,Y,NA,Y,NA,Responder,NA,NA,SER-401 Placebo,9,0,14,0,SER-401 Placebo/EOS,Placebo + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
112-S0001,BL,f__Ruminococcaceae,24621721,26.219021548101363,SGP033356,Ship_6425,Stool - OmniGut Aliquot,A882BZ346-001,10783982-A02-01,2/6/20,PICI0014-112-S0001,Y,Y,112,Massachusetts General Hospital- Boston,66,Female,Other,Not Hispanic or Latino,IIC,IIIC,Cutaneous,NRAS Q61R,Wild Type,High,SER-401 Placebo,2/12/20,ADVERSE EVENT,184,COMPLETED,707,NA,NA,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-13.26923077,SGP033356,Batch191,Y,NA,Y,NA,Responder,NA,25.1,SER-401 Placebo,9,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
112-S0001,C1D1,f__Ruminococcaceae,23408241,25.5375019886874,SGP033355,Ship_6425,Stool - OmniGut Aliquot,A267BX083-002,10783983-A01-A1,2/26/20,PICI0014-112-S0001,Y,Y,112,Massachusetts General Hospital- Boston,66,Female,Other,Not Hispanic or Latino,IIC,IIIC,Cutaneous,NRAS Q61R,Wild Type,High,SER-401 Placebo,2/12/20,ADVERSE EVENT,184,COMPLETED,707,NA,NA,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-13.26923077,SGP033355,Batch191,Y,NA,Y,NA,Responder,NA,25.1,SER-401 Placebo,9,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
112-S0001,C1D8,f__Ruminococcaceae,16799890,26.50154267594233,SGP033361,Ship_6425,Stool - OmniGut Aliquot,A418BX565-002,10783984-A01-A1,3/6/20,PICI0014-112-S0001,Y,Y,112,Massachusetts General Hospital- Boston,66,Female,Other,Not Hispanic or Latino,IIC,IIIC,Cutaneous,NRAS Q61R,Wild Type,High,SER-401 Placebo,2/12/20,ADVERSE EVENT,184,COMPLETED,707,NA,NA,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-13.26923077,SGP033361,Batch191,Y,NA,Y,NA,Responder,NA,25.1,SER-401 Placebo,9,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
112-S0001,C2D1,f__Ruminococcaceae,17277521,25.325588239665684,SGP039586,Ship_7129,Stool - OmniGut Aliquot,A576BY402-002,10849423-A01-A1,3/26/20,PICI0014-112-S0001,Y,Y,112,Massachusetts General Hospital- Boston,66,Female,Other,Not Hispanic or Latino,IIC,IIIC,Cutaneous,NRAS Q61R,Wild Type,High,SER-401 Placebo,2/12/20,ADVERSE EVENT,184,COMPLETED,707,NA,NA,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-13.26923077,SGP039586,Batch234,Y,NA,Y,NA,Responder,NA,25.1,SER-401 Placebo,9,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
112-S0001,C3D1,f__Ruminococcaceae,9270425,14.09818422647319,SGP039590,Ship_7129,Stool - OmniGut Aliquot,A092BZ316-002,10849425-A09-A1,4/22/20,PICI0014-112-S0001,Y,Y,112,Massachusetts General Hospital- Boston,66,Female,Other,Not Hispanic or Latino,IIC,IIIC,Cutaneous,NRAS Q61R,Wild Type,High,SER-401 Placebo,2/12/20,ADVERSE EVENT,184,COMPLETED,707,NA,NA,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-13.26923077,SGP039590,Batch234,Y,NA,Y,NA,Responder,NA,25.1,SER-401 Placebo,9,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
112-S0001,C4D1,f__Ruminococcaceae,12733384,20.808146180327537,SGP039591,Ship_7129,Stool - OmniGut Aliquot,A658BZ498-002,10849426-A01-A1,5/21/20,PICI0014-112-S0001,Y,Y,112,Massachusetts General Hospital- Boston,66,Female,Other,Not Hispanic or Latino,IIC,IIIC,Cutaneous,NRAS Q61R,Wild Type,High,SER-401 Placebo,2/12/20,ADVERSE EVENT,184,COMPLETED,707,NA,NA,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-13.26923077,SGP039591,Batch234,Y,NA,Y,NA,Responder,NA,25.1,SER-401 Placebo,9,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
112-S0001,C7D1,f__Ruminococcaceae,12661920,18.906075495742247,SGP039601,Ship_7129,Stool - OmniGut Aliquot,A942CA880-002,10849427-A01-A1,8/13/20,PICI0014-112-S0001,Y,Y,112,Massachusetts General Hospital- Boston,66,Female,Other,Not Hispanic or Latino,IIC,IIIC,Cutaneous,NRAS Q61R,Wild Type,High,SER-401 Placebo,2/12/20,ADVERSE EVENT,184,COMPLETED,707,NA,NA,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-13.26923077,SGP039601,Batch234,Y,NA,N,"heated at 50 °C for 15-30 min, vortexed prior to subaliquoting, may affect DNA quality",Responder,NA,25.1,SER-401 Placebo,9,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
112-S0001,D-7,f__Ruminococcaceae,13153442,22.98949724814321,SGP033354,Ship_6425,Stool - OmniGut Aliquot,A242BX914-002,10783985-A01-A1,2/20/20,PICI0014-112-S0001,Y,Y,112,Massachusetts General Hospital- Boston,66,Female,Other,Not Hispanic or Latino,IIC,IIIC,Cutaneous,NRAS Q61R,Wild Type,High,SER-401 Placebo,2/12/20,ADVERSE EVENT,184,COMPLETED,707,NA,NA,STABLE DISEASE,SD >= 24 weeks,Responder,Non-responder,-13.26923077,SGP033354,Batch191,Y,NA,Y,NA,Responder,NA,25.1,SER-401 Placebo,9,0,7,1,SER-401 Placebo/EOS,Placebo + Nivolumab,Stable Disease,NA,Stable Disease > 24 weeks,SD
113-S0001,BL,f__Ruminococcaceae,141509,0.1495085664861824,SGP039578,Ship_7129,Stool - OmniGut Aliquot,A138CH876-001,10857851-A01-01,6/17/20,PICI0014-113-S0001,Y,Y,113,Huntsman Cancer Institute,62,Female,White,Not Hispanic or Latino,IIA,IIIC,Cutaneous,NRAS – other mutation,Wild Type,Low,SER-401 Active,6/26/20,COMPLETED,321,COMPLETED,573,NA,NA,COMPLETE RESPONSE,NA,Responder,Responder,-100,SGP039578,Batch234,Y,NA,Y,NA,Responder,40.1,NA,SER-401 Active,12,1,12,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Complete Response,Confirmed PR,NA,CR
113-S0001,C1D1,f__Ruminococcaceae,7896654,12.493634248455274,SGP039593,Ship_7129,Stool - OmniGut Aliquot,A407CA429-002,10831417-A01-A1,7/9/20,PICI0014-113-S0001,Y,Y,113,Huntsman Cancer Institute,62,Female,White,Not Hispanic or Latino,IIA,IIIC,Cutaneous,NRAS – other mutation,Wild Type,Low,SER-401 Active,6/26/20,COMPLETED,321,COMPLETED,573,NA,NA,COMPLETE RESPONSE,NA,Responder,Responder,-100,SGP039593,Batch234,Y,NA,Y,NA,Responder,40.1,NA,SER-401 Active,12,1,12,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Complete Response,Confirmed PR,NA,CR
113-S0001,C2D1,f__Ruminococcaceae,2909430,4.0397511636693295,SGP039599,Ship_7129,Stool - OmniGut Aliquot,A846CA455-002,10857854-A01-A1,8/6/20,PICI0014-113-S0001,Y,Y,113,Huntsman Cancer Institute,62,Female,White,Not Hispanic or Latino,IIA,IIIC,Cutaneous,NRAS – other mutation,Wild Type,Low,SER-401 Active,6/26/20,COMPLETED,321,COMPLETED,573,NA,NA,COMPLETE RESPONSE,NA,Responder,Responder,-100,SGP039599,Batch234,Y,NA,Y,NA,Responder,40.1,NA,SER-401 Active,12,1,12,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Complete Response,Confirmed PR,NA,CR
113-S0001,C3D1,f__Ruminococcaceae,1183442,1.2451497016849662,SGP039603,Ship_7129,Stool - OmniGut Aliquot,A196CB942-002,10874357-A01-A1,9/2/20,PICI0014-113-S0001,Y,Y,113,Huntsman Cancer Institute,62,Female,White,Not Hispanic or Latino,IIA,IIIC,Cutaneous,NRAS – other mutation,Wild Type,Low,SER-401 Active,6/26/20,COMPLETED,321,COMPLETED,573,NA,NA,COMPLETE RESPONSE,NA,Responder,Responder,-100,SGP039603,Batch234,Y,NA,Y,NA,Responder,40.1,NA,SER-401 Active,12,1,12,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Complete Response,Confirmed PR,NA,CR
113-S0001,C4D1,f__Ruminococcaceae,924006,1.4077466209044325,SGP039584,Ship_7129,Stool - OmniGut Aliquot,A659CB959-002,10886654-A01-A1,9/30/20,PICI0014-113-S0001,Y,Y,113,Huntsman Cancer Institute,62,Female,White,Not Hispanic or Latino,IIA,IIIC,Cutaneous,NRAS – other mutation,Wild Type,Low,SER-401 Active,6/26/20,COMPLETED,321,COMPLETED,573,NA,NA,COMPLETE RESPONSE,NA,Responder,Responder,-100,SGP039584,Batch234,Y,NA,Y,NA,Responder,40.1,NA,SER-401 Active,12,1,12,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Complete Response,Confirmed PR,NA,CR
113-S0001,C7D1,f__Ruminococcaceae,1653588,2.6819074592162946,SGP039608,Ship_7129,Stool - OmniGut Aliquot,A963CC177-002,10886653-A01-A1,12/22/20,PICI0014-113-S0001,Y,Y,113,Huntsman Cancer Institute,62,Female,White,Not Hispanic or Latino,IIA,IIIC,Cutaneous,NRAS – other mutation,Wild Type,Low,SER-401 Active,6/26/20,COMPLETED,321,COMPLETED,573,NA,NA,COMPLETE RESPONSE,NA,Responder,Responder,-100,SGP039608,Batch234,Y,NA,Y,NA,Responder,40.1,NA,SER-401 Active,12,1,12,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Complete Response,Confirmed PR,NA,CR
113-S0001,D-7,f__Ruminococcaceae,0,0,SGP039592,Ship_7129,Stool - OmniGut Aliquot,A337CA319-002,10831418-A01-A1,7/2/20,PICI0014-113-S0001,Y,Y,113,Huntsman Cancer Institute,62,Female,White,Not Hispanic or Latino,IIA,IIIC,Cutaneous,NRAS – other mutation,Wild Type,Low,SER-401 Active,6/26/20,COMPLETED,321,COMPLETED,573,NA,NA,COMPLETE RESPONSE,NA,Responder,Responder,-100,SGP039592,Batch234,Y,NA,Y,NA,Responder,40.1,NA,SER-401 Active,12,1,12,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Complete Response,Confirmed PR,NA,CR
113-S0002,BL,f__Ruminococcaceae,13747665,17.748859422728938,SGP039577,Ship_7129,Stool - OmniGut Aliquot,A138CH859-001,10831414-A01-01,7/9/20,PICI0014-113-S0002,Y,Y,113,Huntsman Cancer Institute,64,Male,White,Not Hispanic or Latino,IIA,IV,Cutaneous,NRAS Q61K,BRAF V600E,High,SER-401 Active,7/20/20,COMPLETED,322,COMPLETED,547,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-68.27067669,SGP039577,Batch234,Y,NA,Y,NA,Responder,2.9,NA,SER-401 Active,12,1,12,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
113-S0002,C1D8,f__Ruminococcaceae,9043882,13.97998372247398,SGP039600,Ship_7129,Stool - OmniGut Aliquot,A903CA655-002,10874971-A01-A1,8/11/20,PICI0014-113-S0002,Y,Y,113,Huntsman Cancer Institute,64,Male,White,Not Hispanic or Latino,IIA,IV,Cutaneous,NRAS Q61K,BRAF V600E,High,SER-401 Active,7/20/20,COMPLETED,322,COMPLETED,547,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-68.27067669,SGP039600,Batch234,Y,NA,Y,NA,Responder,2.9,NA,SER-401 Active,12,1,12,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
113-S0002,C2D1,f__Ruminococcaceae,13678882,15.860853970864383,SGP039581,Ship_7129,Stool - OmniGut Aliquot,A184CB802-002,10874972-A01-A1,44075,PICI0014-113-S0002,Y,Y,113,Huntsman Cancer Institute,64,Male,White,Not Hispanic or Latino,IIA,IV,Cutaneous,NRAS Q61K,BRAF V600E,High,SER-401 Active,7/20/20,COMPLETED,322,COMPLETED,547,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-68.27067669,SGP039581,Batch234,Y,NA,Y,NA,Responder,2.9,NA,SER-401 Active,12,1,12,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
113-S0002,C7D1,f__Ruminococcaceae,13908801,20.59088285313629,SGP039610,Ship_7129,Stool - OmniGut Aliquot,A549CD323-002,10887614-A01-A1,1/19/21,PICI0014-113-S0002,Y,Y,113,Huntsman Cancer Institute,64,Male,White,Not Hispanic or Latino,IIA,IV,Cutaneous,NRAS Q61K,BRAF V600E,High,SER-401 Active,7/20/20,COMPLETED,322,COMPLETED,547,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-68.27067669,SGP039610,Batch234,Y,NA,Y,NA,Responder,2.9,NA,SER-401 Active,12,1,12,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
113-S0002,D-7,f__Ruminococcaceae,0,0,SGP039597,Ship_7129,Stool - OmniGut Aliquot,A714CA220-002,10831416-A01-A1,7/28/20,PICI0014-113-S0002,Y,Y,113,Huntsman Cancer Institute,64,Male,White,Not Hispanic or Latino,IIA,IV,Cutaneous,NRAS Q61K,BRAF V600E,High,SER-401 Active,7/20/20,COMPLETED,322,COMPLETED,547,NA,NA,PARTIAL RESPONSE,NA,Responder,Responder,-68.27067669,SGP039597,Batch234,Y,NA,Y,NA,Responder,2.9,NA,SER-401 Active,12,1,12,1,SER-401 Active/EOS,Vancomycin + SER-401 + Nivolumab,Partial Response,Confirmed PR,NA,PR-confirmed
